INTERNATIONAL EDITION
INDEPENDENT WORLD NEWS
Business

Bayer lifts 2026 earnings forecast as pharmaceutical sales strengthen

The German group raised its annual earnings guidance after stronger drug sales, while agricultural profits and cash flow remained under pressure.

Illuminated Bayer Cross sign above buildings in Leverkusen at night.
Archive: the Bayer Cross in Leverkusen, Germany, photographed in 2005; not an image of the 2026 results announcement.
Photo credit and license Photo: Atamari / Wikimedia Commons / CC BY-SA 3.0; archival image from 19 December 2005; no changes made. · Image source · License: CC BY-SA 3.0
Text size

German pharmaceuticals and agriculture group Bayer raised its 2026 earnings forecast on 3 November after its prescription-drug business delivered a stronger third quarter. The company reported group revenue of €10.053 billion, up 4.1% from a year earlier, and earnings before interest, tax, depreciation and amortisation excluding special items of €1.615 billion, up 6.9%.

For the full year, Bayer now expects adjusted group EBITDA of €9.8 billion to €10.3 billion, compared with its previous forecast of €9.6 billion to €10.1 billion. It also improved its free-cash-flow outlook by €1 billion and reduced the range of projected year-end net financial debt to €28 billion to €29 billion. These figures are company forecasts, not final results.

Prescription medicine sales rose 8% on a reported basis to €4.680 billion. Bayer attributed much of that performance to the growth of its cancer treatment Nubeqa and its medicine Kerendia, used for certain kidney and heart conditions. It said the pharmaceutical division’s adjusted EBITDA increased 23.6% to €1.292 billion.

The improvement was uneven. The Crop Science division faced weaker demand in some markets and higher costs; its adjusted EBITDA fell 41.3% to €101 million in the seasonally smaller quarter. Consumer Health earnings also slipped. The group recorded a net loss of €672 million, despite the improvement from the year-earlier period.

The results highlight the difference between operational momentum in individual businesses and the broader financial challenges confronting Bayer. Stronger medicine sales support its upgraded outlook, but debt, litigation-related payments and pressure on agriculture remain important constraints. The figures come from Bayer’s quarterly announcement and have been reported separately by Reuters.